Literature DB >> 10217420

The RAMP2/CRLR complex is a functional adrenomedullin receptor in human endothelial and vascular smooth muscle cells.

S Kamitani1, M Asakawa, Y Shimekake, K Kuwasako, K Nakahara, T Sakata.   

Abstract

Adrenomedullin, a potently hypotensive peptide isolated from human pheochromocytoma, is known to elicit a rise in cAMP levels within mammalian endothelial and smooth muscle cells. Until now, however, little has been known about the adrenomedullin receptor. Recently, a group called receptor activity-modifying proteins that complex with the calcitonin receptor-like receptor, and thereby regulate its transport and ligand specificity, were identified. Here we show that mRNA for both the calcitonin receptor-like receptor and the receptor activity-modifying protein 2, but not the receptor activity-modifying protein 1 or receptor activity-modifying protein 3, are expressed in human endothelial and vascular smooth muscle cells. We also found that adrenomedullin increased cAMP levels in HeLa EBNA and 293 EBNA cells, expressing both the receptor activity-modifying protein 2 and calcitonin receptor-like receptor proteins. Thus, the receptor activity-modifying protein 2/calcitonin receptor-like receptor complex apparently serves as a functional adrenomedullin receptor in human endothelial and vascular smooth muscle cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10217420     DOI: 10.1016/s0014-5793(99)00358-0

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  16 in total

1.  CGRP and adrenomedullin binding correlates with transcript levels for calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) in rat tissues.

Authors:  P Chakravarty; T P Suthar; H A Coppock; C G Nicholl; S R Bloom; S Legon; D M Smith
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

2.  Adrenomedullin and nitric oxide in children with detrusor instability.

Authors:  Ayşe Balat; Kemal Sarica; Mustafa Cekmen; Muhittin Yürekli; Faruk Yağci; Ahmet Erbağci
Journal:  Pediatr Nephrol       Date:  2003-04-08       Impact factor: 3.714

3.  AM₁-receptor-dependent protection by intermedin of human vascular and cardiac non-vascular cells from ischaemia-reperfusion injury.

Authors:  David Bell; Malcolm Campbell; Matthew Ferguson; Leah Sayers; Liz Donaghy; Anna O'Regan; Victoria Jewhurst; Mark Harbinson
Journal:  J Physiol       Date:  2011-12-19       Impact factor: 5.182

4.  Mechanisms responsible for vascular hyporesponsiveness to adrenomedullin after hemorrhage: the central role of adrenomedullin binding protein-1.

Authors:  Rongqian Wu; Xiaoxuan Cui; Weifeng Dong; Mian Zhou; H Hank Simms; Ping Wang
Journal:  Ann Surg       Date:  2005-07       Impact factor: 12.969

5.  Picomolar Affinity Antagonist and Sustained Signaling Agonist Peptide Ligands for the Adrenomedullin and Calcitonin Gene-Related Peptide Receptors.

Authors:  Jason M Booe; Margaret L Warner; Augen A Pioszak
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-24

6.  Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress.

Authors:  Makoto Hagiwara; Grant Bledsoe; Zhi-Rong Yang; Robert S Smith; Lee Chao; Julie Chao
Journal:  Am J Physiol Renal Physiol       Date:  2008-10-01

Review 7.  Cellular functions of NSF: not just SNAPs and SNAREs.

Authors:  Chunxia Zhao; John T Slevin; Sidney W Whiteheart
Journal:  FEBS Lett       Date:  2007-03-21       Impact factor: 4.124

Review 8.  Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems.

Authors:  D Bell; B J McDermott
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

Review 9.  Vascular endothelial dysfunction and pharmacological treatment.

Authors:  Jin Bo Su
Journal:  World J Cardiol       Date:  2015-11-26

10.  Comparison of the expression of calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) with CGRP and adrenomedullin binding in cell lines.

Authors:  Tejal Choksi; Debbie L Hay; Stephen Legon; David R Poyner; Stefanie Hagner; Stephen R Bloom; David M Smith
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.